Press Releases

Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer

Panbela Provides Business Update and Reports Q1 2023 Financial Results

Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023

Panbela Announces Poster Presentation at American Association for Cancer Research

Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer

First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine

Panbela Regains Worldwide Rights to Develop and Commercialize Flynpovi™ in Patients with Familial Adenomatous Polyposis (FAP)

Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting

Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting

Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine

Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101

Patent developed in collaboration with Syngene International Ltd.